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Antiretroviral treatment (ART) is a powerful tool for reducing 
both AIDS mortality1,2 and HIV transmission.3 The monitoring 
of access to ART is therefore critical to the evaluation of the 
impact of HIV treatment and prevention programmes. Previous 
monitoring exercises have shown that, since the announcement 
of a comprehensive care, management and treatment programme 
by the South African Department of Health in late 2003, access to 
ART in South Africa has increased dramatically.4,5 These assessments 
suggested that South Africa was on track to meet the targets laid out 
in the 2007 - 2011 National Strategic Plan (NSP) for HIV/AIDS and 
Sexually Transmitted Infections, which aimed to achieve new ART 
enrolment numbers equal to 80% of the number of newly eligible 
individuals in each year, by 2011.6 However, there has not as yet been 
any formal assessment of whether this target has been met.
The monitoring of access to ART in South Africa is challenging for 
several reasons. The interpretation of public sector statistics is 
complicated by changes in reporting practices in late 2009, with 
most provinces switching from reporting numbers of patients 
cumulatively started on ART to numbers of patients currently 
on ART. Statistics from disease management programmes and 
programmes run by non-governmental organizations (NGOs) have 
not been routinely collected and reported. In addition, there is 
generally a lack of information on the age and sex of patients. This 
is particularly problematic in view of concerns that ART initiation 
rates may be lower among men than women.7-9
The estimation of ART coverage is also hampered by uncertainty 
regarding the ‘treatment need’, the denominator in the coverage 
calculation. Mathematical models have been used to estimate 
numbers of HIV-positive individuals with CD4 counts below 
different thresholds, but there is substantial uncertainty 
surrounding the rates of CD4 decline that are assumed in these 
models, and there is also growing recognition that these rates 
of CD4 decline may differ between populations.10 There is also 
concern that cross-sectional measures of ART coverage may fail to 
give a sense of recent programme performance, which is better 
reflected in the ratio of the number of patients starting ART in 
a year to the number of individuals becoming eligible for ART in 
the same year.11 The latter measure has the advantage of being 
consistent with the way in which the South African NSP targets are 
expressed, and is also less sensitive to model assumptions about 
rates of CD4 decline and ART eligibility criteria.11
The objective of this paper is to assess recent changes in access to 
ART in South Africa, and to evaluate the extent to which the 2007 
- 2011 NSP treatment targets have been met. This study also aims 
to improve on previous work4 by including more recent programme 
statistics, by using locally relevant CD4 data in the estimation of 
the treatment need, by including 95% confidence intervals (CIs) 
in coverage estimates, and by estimating coverage separately for 
men, women and children.
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Background. South Africa’s National Strategic Plan (NSP) for 2007 - 2011 aimed to achieve new antiretroviral treatment (ART) enrol-
ment numbers equal to 80% of the number of newly eligible individuals in each year, by 2011.
Objectives. To estimate ART coverage in South Africa and assess whether NSP targets have been met.
Methods. ART data were collected from public and private providers of ART. Estimates of HIV incidence rates were obtained from inde-
pendent demographic projection models. Adult ART data and incidence estimates were entered into a separate model that estimated 
rates of progression through CD4 stages, and the model was fitted to South African CD4 data and HIV prevalence data.
Results. By the middle of 2011, the number of patients receiving ART in South Africa had increased to 1.79 million (95% CI 1.65 - 1.93 
million). Adult ART coverage, at the previous ART eligibility criterion of CD4 <200/μl, was 79% (95% CI 70 - 85%), but reduced to 
52% (95% CI 46 - 57%) when assessed according to the new South African ART eligibility criteria (CD4<350/μl). The number of adults 
starting ART in 2010/11 was 1.56 times (95% CI 1.08 - 1.97) the number of adults who became ART-eligible in 2010/11, well in excess 
of the 80% target. However, this ratio was substantially higher in women (1.96, 95% CI 1.33 - 2.51) than in men (1.23, 95% CI 0.83 - 
1.58) and children (1.13, 95% CI 0.74 - 1.48).
Conclusion. South Africa has exceeded the ART targets in its 2007 - 2011 NSP, but men and children appear to be accessing ART at a 
lower rate than women.
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METhOds
ART pROGRAMME sTATIsTICs
Public sector ART programme statistics to the end of June 2011 
were obtained from the South African Department of Health, and 
were adjusted to achieve consistency of definition (cumulative/
current), using a previously described formula,4 for each province. 
Unpublished data on the sex ratio of adult patients enrolled in 
public ART programmes in four provinces, collected up to March 
2009, were used to estimate the sex ratio of adults starting ART in 
the public sector.
Private sector data and data from NGOs were obtained through 
surveys conducted every two years, since mid-2006.12 Linear 
interpolation and extrapolation was used to estimate numbers for 
programmes with missing data and for years in which no survey 
was conducted. Estimates of the proportion of private sector 
patients who were men, women and children were obtained from 
submissions by medical schemes to the Risk Equalization Fund 
up to March 2008, and the geographical distribution of private 
sector patients was estimated from early private sector statistics.13 
Detailed data collected from NGO programmes in the 2008 survey 
were used to determine the profile of NGO patients by age, sex and 
province.
MAThEMATICAL MOdEL
To estimate the numbers of adults needing ART, a mathematical 
model was developed to simulate the growth of the South African 
population over time, the incidence of HIV and the decline in CD4 
counts in HIV-positive adults. The model stratifies the population 
by age and sex, and projects the change in population in one-year 
intervals, starting in the middle of 1985. Assumptions regarding 
the age- and sex-specific population profile, non-HIV mortality, 
fertility, migration and HIV incidence are based on the ASSA2008 
AIDS and Demographic model.14 Once infected, individuals are 
assumed to progress through a four-stage model of CD4 decline, in 
the absence of ART (Fig. 1). Individuals are assumed to experience 
AIDS mortality in the CD4 200 - 349/µl category at a fraction θ of 
the AIDS mortality rate in the CD4<200/µl category, if untreated. 
Up to mid-2009, adults of sex g are assumed to start ART only once 
their CD4 count has dropped below 200/µl, at a rate of rg(t) per 
annum in year t. Between mid-2009 and mid-2011, the model also 
allows individuals to start ART in the CD4 200 - 349 category if they 
develop tuberculosis or become pregnant, following the change in 
South African ART guidelines in early 2010.15 The rg(t) rates in each 
year are calculated from the ART programme statistics (further 
detail is provided in the online appendix).
Adults who start ART are assumed to be lost to the ART programme 
with probability κ0 during the first 6 months after starting ART, 
and with probability κ1 for each year after the first 6 months. This 
does not include individuals who temporarily interrupt ART. Of 
those leaving the ART programme permanently, a proportion ν are 
assumed to leave the programme owing to HIV-related mortality, 
and the remaining proportion (1 – ν) are assumed to stop taking 
their drugs, after which their mortality risk is assumed to be the 
same as that of ART-naïve adults with CD4 counts below 200/µl.
Estimates of annual numbers of new paediatric HIV infections 
were obtained from a separate model of paediatric HIV in South 
Africa.16 Since paediatric ART guidelines recommend ART initiation 
in all HIV-infected children aged <12 months, regardless of 
their immunological or clinical status,17 the annual number of 
new paediatric HIV infections is used to approximate the annual 
number of children newly eligible for ART (the denominator in the 
ART enrolment ratio).
CALIBRATION ANd uNCERTAINTy ANALysIs
The parameters determining the rates of CD4 decline, HIV-related 
mortality and ART discontinuation are estimated by fitting the model 
to HIV prevalence data from the 2005 and 2008 Human Sciences 
Research Council (HSRC) household surveys,18,19 and to CD4 data 
from HIV-positive adults in three South African surveys,20-22 using a 
Bayesian melding procedure.23,24 A detailed explanation is provided 
in the online appendix. Briefly, prior distributions are specified 
to represent uncertainty regarding the parameters of interest, 
including the range of plausible values for the average time to 
starting ART after becoming eligible (1/rg(t)). Prior distributions are 
also specified to represent uncertainty regarding the accuracy of the 
reported ART programme statistics in each year. This uncertainty and 
the uncertainty regarding ART attrition rates affect the model ART 
enrolment inputs. A likelihood function is specified to represent how 
well the model fits the CD4 data and HIV prevalence data, for a given 
set of parameter values. The posterior distribution, representing the 
parameter combinations from the prior distributions that have the 
highest likelihood values, is then simulated by Sampling Importance 
Resampling.25
REsuLTs
The posterior estimates of the model parameters are summarised 
in Table 1, and posterior estimates of numbers of patients receiving 
ART are summarised in Table 2. Over the period mid-2004 to mid-
2011, the total number of patients receiving ART in South Africa 
increased from 47 500 (95% CI 42 900 – 51 800) to 1.79 million 
(95% CI 1.65 - 1.93 million). Of the latter, 85% were receiving ART 
through the public health sector, 11% were receiving ART through 
disease management programmes in the private sector, and the 
remaining 4% were receiving ART through community treatment 
programmes run by NGOs. The majority (61%) of patients were 
women aged 15 or older, men accounted for 31% of patients, 
and children under the age of 15 comprised the remaining 8% of 
patients. KwaZulu-Natal and Gauteng were the two provinces with 
the largest numbers of patients, together accounting for 56% of all 
patients receiving ART.
Changes over time in numbers of treated and untreated adults in 
different CD4 stages are shown in Fig. 2. As at mid-2011, untreated 
HIV-positive adults included 58 000 (95% CI 13 000 – 147 000) 
individuals who had stopped ART, 385 000 (95% CI 247 000 – 634 
000) ART-naive adults with CD4 <200/μl, 1.06 million (95% CI 0.88 
- 1.29 million) with CD4 counts of 200 - 349/μl, 0.74 million (95% 
CI 0.61 - 0.91 million) with CD4 counts of 350 - 500/μl, and 0.94 
million (95% CI 0.77 - 1.16 million) with CD4 counts >500/μl. The 
Fig. 1. Multi-state model of decline in CD4 count and ART initiation by 
HIV-infected adults. All states are stratified by age and sex, and all HIV-
infected adults are assumed to experience age-specific mortality unrelated 
to HIV (not shown).
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total unmet need in the middle of 2011 (ART-naïve adults with CD4 
<350/μl plus all adults who had stopped ART) was 1.50 million 
(95% CI 1.24 - 1.84 million), which is 32% lower than the total 
unmet need four years previously. Estimates of adult ART coverage 
and ART enrolment ratios are shown in Fig. 3. Using previous CD4 
thresholds for defining ART eligibility (CD4 <200/μl), the fraction 
of adults eligible to receive ART who were actually on ART increased 
from 5.1% (95% CI 4.2 - 6.1%) in the middle of 2004 to 79% (95% 
CI 70 - 85%) by the middle of 2011. However, using the new CD4 
thresholds for defining ART eligibility (CD4 <350/μl), adult ART 
coverage by the middle of 2011 was 52% (95% CI 46 - 57%).
As noted previously,11 ART enrolment ratios are similar when using 
different CD4 thresholds to define ART eligibility. For example, 
TABLE 2. NuMBERs OF pATIENTs RECEIVING ART IN sOuTh AFRICA
2004 2005 2006 2007 2008 2009 2010 2011
Currently on ART*
   Total 47 500 110 900 235 000 382 000 588 000 912 000 1 287 000 1 793 000
   By sex/age
      Men 17 700 37 500 75 000 120 000 183 000 283 000 396 000 551 000
      Women 25 600 63 600 138 000 228 000 354 000 553 000 777 000 1 090 000
      Children (<15) 4 200 9 800 22 000 35 000 51 000 76 000 113 000 152 000
   By provider
      Public sector 9 600 60 600 163 000 290 000 470 000 748 000 1 073 000 1 525 000
      Private sector 34 100 43 800 57 000 68 000 86 000 117 000 154 000 190 000
      NGO programmes 3 900 6 400 15 000 24 000 32 000 47 000 60 000 78 000
   By province
      Eastern Cape 5 300 12 600 26 000 43 000 65 000 98 000 137 000 187 000
      Free State 2 200 4 900 10 000 18 000 29 000 47 000 66 000 91 000
      Gauteng 13 800 30 800 62 000 95 000 145 000 219 000 280 000 439 000
      KwaZulu-Natal 12 800 30 300 67 000 110 000 174 000 282 000 409 000 558 000
      Limpopo 2 000 4 800 12 000 21 000 36 000 60 000 101 000 124 000
      Mpumalanga 3 300 5 800 12 000 24 000 38 000 61 000 96 000 142 000
      Northern Cape 400 1 500 3 000 7 000 9 000 13 000 16 000 19 000
      North West 2 700 8 800 21 000 34 000 48 000 70 000 96 000 126 000
      Western Cape 5 000 11 400 21 000 31 000 45 000 64 000 85 000 107 000
Started ART last year
†
   Men 8 400 22 400 43 000 52 000 75 000 118 000 138 000 189 000
   Women 13 700 42 600 84 000 104 000 149 000 235 000 273 000 380 000
   Children (<15) 2 700 6 400 13 000 15 000 20 000 29 000 45 000 48 000
   Total 24 800 71 300 140 000 172 000 243 000 382 000 456 000 617 000
All numbers are rounded to the nearest 1000 (except in the case of 2004 and 2005 totals, which are rounded to the nearest 100). Due to rounding, some rows may not sum to the total. All estimates are 
posterior averages (95% confidence intervals not shown).
*Totals reflect numbers at the middle of each year.
†
Totals reflect ART enrolment over the 12 months up to the middle of the year.
TABLE 1. pOsTERIOR EsTIMATEs OF MOdEL pARAMETERs
symbol Mean (95% CI)
Parameters for untreated adults
   Annual rate of progression from CD4 >500 to 350 - 500 λ1 0.34 (0.28 - 0.39)
   Annual rate of progression from CD4 350 - 500 to 200 - 349 λ2 0.48 (0.40 - 0.58)
   Annual rate of progression from CD4 200 - 349 to <200 λ3 0.32 (0.25 - 0.39)
   Annual rate of HIV mortality if CD4 <200 λ4 0.21 (0.16 - 0.27)
   Ratio of HIV mortality at CD4 200 - 349 to HIV mortality at CD4 <200 θ 0.13 (0.05 - 0.24)
Parameters for treated adults
   Probability of permanent loss to care in first 6 months after ART start κ0 0.078 (0.028 - 0.141)
   Annual probability of permanent loss to care after first 6 months of ART κ1 0.048 (0.018 - 0.087)
   Proportion of permanent loss to care that is due to death ν 0.74 (0.53 - 0.92)
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over the period from mid-2010 to mid-2011, the ratio of the 
number of adults starting ART to the number of adults whose 
CD4 counts fell below the CD4 threshold was 1.64 (95% CI 1.11 
- 2.10) when the CD4 threshold was 200, and 1.56 (95% CI 1.08 
- 1.97) when the CD4 threshold was 350. Both ratios are roughly 
double the target of 80% set in the 2007 - 2011 NSP, and indicate 
substantial progress in removing the ‘backlog’ of unmet need that 
accumulated in previous years.
Estimates of ART access are presented separately for men, women 
and children in Fig. 4. Using the CD4 threshold of 350/μl as the 
criterion for ART eligibility, the fraction of ART-eligible women 
who were receiving ART by the middle of 2011 (60%, 95% CI 53 
- 65%) was significantly higher than the fraction of ART-eligible 
men who were on treatment (41%, 95% CI 36 - 46%). A similar 
difference in magnitude is seen in the ART enrolment ratio over 
the period mid-2010 to mid-2011: using the same ART eligibility 
criterion of CD4 <350/μl, the enrolment ratio was 1.96 (95% CI 
1.33 - 2.51) in women and 1.23 (95% CI 0.83 - 1.58) in men. Over 
the same period, the ratio of the number of children starting ART 
to the number of new infections in children was 1.13 (95% CI 
0.74 - 1.48). In most previous years, this ratio was below both 
the male ART enrolment ratio and the female ART enrolment 
ratio.
dIsCussION
South Africa has made impressive progress in the rollout of ART 
since the start of the public sector ART programme in 2004. The 
number of patients who started ART in 2010/2011 was well in 
excess of the number of individuals who became eligible to receive 
ART over the same period, exceeding the targets set in the 2007 
- 2011 NSP. The unmet need for ART was also reduced by 32% 
between 2007 and 2011. According to the ART initiation criteria 
that were in place at the time, adult treatment coverage by mid-
2011 was close to 80%.
However, there appear to be substantial differences between men, 
women and children in the rate of ART initiation. The low rate of 
ART initiation in men relative to women may be a reflection of 
gender differences in health-seeking behaviour and perceptions 
that men who seek care are ‘weak’.9 Alternatively, the high rate of 
ART initiation in women may be due to higher rates of HIV diagnosis 
through antenatal screening. The relatively low rates of ART 
initiation in children are probably attributable to the lower rates 
of HIV testing in children and the greater complexity of paediatric 
ART relative to adult ART.26 However, it is difficult to compare adult 
and paediatric measures of ART access meaningfully because the 
course of HIV infection is so different in children, with many HIV-
infected infants dying in the first few months of life before there is 
an opportunity for testing.
This analysis extends previous work4 by including assessment of 
uncertainty and by incorporating several new data sources. The 
95% CIs that have been estimated reflect uncertainty regarding 
rates of CD4 decline, rates of mortality and rates of ART retention, 
and also reflect uncertainty regarding the accuracy of reported 
ART programme statistics. However, the CIs do not reflect the 
uncertainty regarding the HIV incidence rates that have been 
estimated from the ASSA2008 model, and this may lead to some 
exaggeration of precision. CIs around the ART enrolment ratios are 
considerably wider in 2009/10 and 2010/11 than in previous years, 
owing to the change in the way that the Department of Health has 
reported public sector ART programme statistics.
Various attempts were made to validate the reported ART 
programme statistics using data from external sources, with 
limited success. Lamivudine sales figures from Aspen Pharmacare, 
which until recently supplied 80% of lamivudine in the public 
sector, were used to obtain crude estimates of numbers of public 
sector patients on treatment in each quarter. These estimates were 
Fig. 2. Numbers of HIV-positive adults, by CD4 count and ART status. 
Numbers exclude paediatric HIV infections. Bars represent posterior means 
(95% confidence intervals not shown).
Fig. 3. Adult ART access. Bars represent posterior means and error bars represent 95% confidence intervals. Dashed line in panel (b) represents 2007 - 
2011 National Strategic Plan target.
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not significantly different from the model estimates in Table 2 up 
to the end of 2008, and from October 2009 to March 2010, but 
were substantially lower than the model estimates from January to 
September of 2009. Numbers of viral load tests performed by the 
National Health Laboratory Service for public sector clinics were 
also used to obtain theoretical estimates of numbers of patients 
receiving ART, on the assumption that patients went for viral 
load testing twice per annum on average. The resulting estimates 
were slightly higher than the corresponding model estimates up 
to 2008, but were 18% lower than the model estimates in 2009. 
Finally, the model estimate of the fraction of the 15 - 49-year-
old population on ART in the middle of 2008 was compared 
with the corresponding proportion estimated in the 2008 HSRC 
national household survey,27 based on testing for the presence of 
antiretroviral drugs in blood samples: the model estimate of 1.8% 
(95% CI 1.6 - 2.0%) was found to be significantly lower than that 
measured in the survey (3.0%). External data sources therefore do 
not provide a clear and consistent assessment of the plausibility 
of the model estimates derived from reported ART programme 
statistics.
Although attempts were made to produce estimates of ART 
coverage for each province, it was not possible to produce plausible 
results for two provinces (Gauteng and Western Cape) because 
the estimated numbers of patients starting ART in recent years 
exceeded the estimated numbers of patients eligible to receive ART, 
in both of these provinces. This could possibly be due to individuals 
with advanced HIV migrating to urban areas because of the 
perceived superiority of health services in the major urban centres 
of Gauteng and Western Cape. The model assumes migration to 
be independent of HIV status, and may therefore under-estimate 
the number of HIV-infected ART-eligible individuals who migrate 
into these provinces. Alternatively, the problems experienced in 
producing plausible results for Gauteng and Western Cape may be 
due to assumed HIV incidence rates in these provinces being too 
low, or reported numbers of ART patients in these provinces being 
exaggerated.
Many challenges exist, both in achieving future ART rollout targets 
and in monitoring future progress towards meeting these targets. 
The new NSP for the 2012 - 2016 period28 proposes targets that 
are much more ambitious than those in the previous NSP: the 
ART enrolment target in 2016 is 80% of the new ART need in 
that year plus 80% of the unmet need from previous years. High 
levels of HIV testing and counselling, as well as expansion of 
capacity to deliver ART, will be required to meet these targets. The 
new NSP for the 2012 - 2016 period proposes several measures 
to strengthen the monitoring and evaluation of South Africa’s 
ART programme, including the introduction of a single patient 
identifier in the health sector and a single registry at the primary 
care level. It is hoped that these measures will lead to greater 
precision in the estimation of ART coverage in future, as well as 
a deeper understanding of the factors determining access to care 
and retention in care.
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This appendix provides further detail regarding the method used to model adult ART 
initiation. It also includes a detailed explanation of the Bayesian melding procedure: the prior 
distributions and the data sources on which they are based, the method used to define the 
likelihood function and the method used to simulate the posterior distribution. 
 
1. Method used to model adult ART initiation 
 
The model inputs are the numbers of adults of sex g starting ART in year t, Sg(t). These are 
used to calculate rg(t), the rate of ART initiation in adults of sex g, who are ART-naïve and 
with CD4 counts <200/μl, during year t. Prior to the change in ART guidelines in 2009, the 
rate rg(t) can be calculated in terms of Sg(t), if we have the model estimates of the numbers of 
individuals who are ART-eligible at the start of year t, Eg(t), as well as the numbers who 
become eligible over the course of year t, Pg(t), and the rate of mortality in untreated ART-
eligible adults, λ4. If it is assumed that the individuals who progress to CD4 <200/μl do so 
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This formula is used to calculate the rate of ART initiation, rg(t), using Newton‟s method. 
Following the change in ART guidelines in 2009, a modified version of the above equation is 
used, to exclude individuals with CD4 counts of 200-349/μl who start ART when they have 
TB or are pregnant. If Bg(x,t) is the model estimate of the number of adults aged x, of sex g, 
who have CD4 counts of 200-349/μl at the start of year t, then the left hand side of the above 
equation changes to 
 
  utxftxBttS g
x
gg   ),(),()()( , 
 
where Ω(t) is the fraction of HIV-positive TB patients and pregnant women who start ART in 
year t, if their CD4 count is below 350/μl, fg(x,t) is the fertility rate in year t at age x, and u is 
the TB incidence rate in HIV-positive individuals with CD4 counts of 200-349/μl. Equation 
(1) is therefore modified so that the left-hand side includes only those individuals who start 
ART with a CD4 count of <200/μl. A limitation of this formula is that it considers only the 
number of adults with CD4 200-349/μl at the start of the year, and does not consider 
movements into and out of the CD4 200-349/μl state during the course of the year. However, 
since the movements into and out of the CD4 200-349/μl state offset one another to some 
extent, the change in Bg(x,t) over a single year is likely to be modest, and the approximation 
is therefore reasonable.  
 
The parameters in the above equation are estimated from various sources. The fertility rates 
by age and year are obtained from the ASSA2008 AIDS and Demographic model,
1
 and have 
2 
 
been set to zero in the case of males. The annual TB incidence rate u, in adults with CD4 
200-349/μl, is set to 0.043, based on data from HIV patients in two provinces, Gauteng and 
Mpumlanga.
2, 3
 The proportion of TB patients and pregnant women who are assumed to start 
ART, if their CD4 count is in the CD4 200-349 range, is set to 30% in 2009/10 (since the 
change in guideline was only announced at the end of 2009 and formal guidelines were only 
published in early 2010) and to 75% in 2010/11. The latter assumption may be optimistic, as 
South African studies have generally found that the proportion of ART-eligible pregnant 
women who initiate ART before delivery is typically 30-60%,
4-7
 and only one South African 




The same assumptions regarding fertility rates and TB incidence rates are used in allowing 
for ART initiation in the CD4 200-349/μl category. 
 
2. Prior distributions 
 
Prior distributions are specified for various model parameters to reflect the extent of 
uncertainty that exists a priori, before calibrating the model to CD4 data and HIV prevalence 
data. The sections that follow provide the justification for the prior distributions that have 
been chosen for each parameter. In general, gamma distributions have been chosen to 
represent uncertainty regarding parameters that can take on any positive value, beta 
distributions have been chosen to represent uncertainty regarding parameters that can take on 
any value between 0 and 1, and normal distributions have been chosen to represent 
uncertainty regarding parameters that can take on any value. The distributions have therefore 
been chosen according to the range of values that they support, since the gamma, beta and 
normal distributions are defined on the ranges [0, ∞), [0, 1] and (-∞, ∞) respectively. 
 
(a) Rates of CD4 decline in the absence of ART 
 
The model that is used to describe progression to death in HIV-infected adults, in the absence 
of ART, is illustrated in Figure 1. All infected adults are assumed to have initial CD4 counts 
above 500 (based on the CD4 distributions observed in HIV-negative South Africans
9, 10
), 
which decline over the course of HIV infection. The risk of AIDS mortality is assumed to 
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In setting the prior distributions on the rates of CD4 decline (λ1, λ2, and λ3), we review 
estimates from other studies that have attempted to estimate rates of CD4 decline in untreated 
HIV-positive individuals, prior to the availability of ART. Estimates obtained from three 
studies are summarized in Table 1. All of these studies are based on cohorts in high income 
countries with HIV-1 subtype B epidemics, and the rates of CD4 decline estimated in these 
studies might therefore not be appropriate to South Africa. Estimates of λ1 lie between 0.38 
and 0.60 (average of 0.44), but these values are likely to be over-estimates of the rate of 
transition out of the CD4 >500 state. This is because in all three studies the CD4 >500 
category was actually separated into three states (CD4 >900, CD4 700-900 and CD4 500-
699), and the transition intensities shown in Table 1 are the rates of transition from the CD4 
500-699 state to the CD4 350-499 state. (Calculating the rate of transition out of the >500 
category would mean increasing the denominator without changing the numerator.) Because 
of the likely over-statement, we set the prior distribution for the λ1 parameter to be gamma 
with a mean of 0.3 and a standard deviation of 0.06 (so that the 97.5 percentile of the 
distribution is 0.43, close to the average of the studies in Table 1). 
 
Estimates of the λ2 parameter lie between 0.30 and 0.51 (average value of 0.38). We choose a 
gamma distribution with a mean of 0.40 and a standard deviation of 0.08 to represent our 
prior uncertainty regarding this parameter. The 2.5 and 97.5 percentiles of this distribution 
are 0.26 and 0.58 respectively, an interval that includes all of the empirical estimates in Table 
1. Finally, estimates of λ3 lie between 0.26 and 0.49. However, the estimate of Longini et al 
11
 
is likely to be an over-estimate because the model assumes that individuals can only develop 
AIDS-defining illnesses when their CD4 count is <200, so that individuals who develop 
AIDS with CD4 >200 are artificially “pushed through” into the CD4 <200 category. If the 
estimate of Longini et al is excluded, the average estimate of the λ3 parameter is 0.36. To 
represent the prior uncertainty regarding this parameter we therefore choose a gamma 
distribution with a mean of 0.35 and a standard deviation of 0.07. The 2.5 and 97.5 
percentiles of this distribution are 0.23 and 0.50 respectively. 
 
Table 1: Estimated annual rates of CD4 decline in the absence of ART 
Study Population 












 Men in San Francisco, 
   1984-92 
0.42 0.37 0.49 
Hendriks et al
13*
 Men in Amsterdam, 1985-90 0.38 0.34 0.34 
Men in Amsterdam, 1990-97 0.39 0.30 0.26 
Men in Vancouver, 1985-90 0.40 0.37 0.31 
Men in Vancouver, 1990-97 0.45 0.36 0.39 
Longini et al
11
 USA army personnel, 
   1985-90 
0.60 0.51 0.49 
Average  0.44 0.38 0.38 
* Model allows for reversible CD4 declines, and the transition intensities shown here are the „net‟ rates of 







(b) Rates of HIV mortality in the absence of ART 
 
In setting the prior distributions to represent the uncertainty regarding the mortality rates in 
different CD4 categories, we review African studies of mortality in HIV-positive individuals 
not receiving ART. Table 2 summarizes the evidence from various African studies. In one 
study,
14
 mortality rates were reported both for patients receiving cotrimoxazole (CTX) and 
patients not receiving CTX, but only the former is included in Table 2, as the provision of 
CTX to HIV-positive patients has been the standard of care in South Africa for many years. 
In seven studies that estimated the annual mortality rate in patients with CD4 below 200/μl, 
who were not receiving ART, estimates ranged from 0.14 to 0.39 (average value of 0.26). To 
represent the prior uncertainty regarding the λ4 parameter we therefore choose a gamma prior 
with a mean of 0.25 and a standard deviation of 0.07 (this distribution has 2.5 and 97.5 
percentiles of 0.13 and 0.40 respectively).  
 
Estimates of the ratio of mortality in the CD4 200-349/μl category to that in the <200/μl 
category (θ) range between 0.12 and 0.30 (average value of 0.22). However, these are likely 
to be over-estimates for two reasons. Firstly, because CD4 testing is not frequent, the CD4 
count at the time of death is likely to be lower than the last measured CD4 count; this means 
that the rate of mortality in the CD4 200-349/μl category is likely to be over-estimated if it is 
assumed that the CD4 count at death is the same as the same as the last measured CD4 count. 
Secondly, CD4 measurements are highly variable, with recorded CD4 values fluctuating 
considerably around a notional „true‟ value, even in the course of a single day.
15-17
 Since we 
are modelling only the „true‟ value and not the fluctuations in recorded values, and since the 
mortality risk is likely to depend on the cumulative incidence of opportunistic infections over 
several days or weeks, the strength of association between the mortality risk and the true CD4 
is likely to be understated by the observed association between the mortality risk and the 
measured CD4. A stronger association would imply a lower value of θ. We therefore set the 
prior distribution for θ to be beta with a mean of 0.15 and a standard deviation of 0.05 (the 
2.5 and 97.5 percentiles of this distribution are 0.07 and 0.26 respectively). 
 
Table 2: Estimated rates of mortality in the absence of ART 
Study Population 
Frequency 
of CD4  
testing 












 Cape Town At least 
6-monthly 
0.08 0.27 0.30 
Hargrove et al
19
 Zimbabwean women 
   followed postpartum 
Only at 
baseline 
0.0293* 0.1442 0.20 
Coutsoudis et al
10
 Women in KwaZulu-Natal 
   followed postpartum 
Only at 
baseline 
- 0.1714 - 
Mermin et al
14
 Ugandan patients,  
   receiving CTX 
 - 0.392 - 
Van Oosterhout et al
20
 Blantyre, Malawi 4-monthly 0.04 0.34 0.12 
Seyler et al
21
 Abidjan, Côte d‟Ivoire 
   (patients receiving CTX) 
6-monthly 0.077 0.316 0.24 
eART-linc
22
 Patients from Uganda and 
   Côte d‟Ivoire 
 - 0.192 - 
Average   0.06 0.26 0.22 




(c) Rate of attrition after ART initiation 
 
The probability of attrition in the first 6 months is calculated as Rk00  , and the annual 
probability of attrition after the first 6 months is calculated as Rk11  . In these equations, 
0k  and 1k  represent the „base rates‟, and R is the ratio of the true attrition rates to the base 
rates. The base parameters 0k  and 1k  have been set at 0.105 and 0.065 respectively, based on 
data from the Western Cape public sector programme.
23
 A gamma prior distribution is 
specified for parameter R, to represent the uncertainty regarding the true attrition rates. This 
prior distribution has a mean of 1, so that the prior means on parameters 0  and 1 are the 
same as the values assumed previously.
24
 In order to set the variance of the prior distribution, 
it is necessary to examine the variability in attrition rates between settings. Table 3 compares 
cumulative rates of attrition by 12 months after starting ART in various South African 
programmes. Rates of attrition by 12 months reach as high as 25% and 28% in the studies of 
Ford et al and Rosen et al respectively, almost double the rates of attrition in the Western 
Cape as a whole. However, it is possible that the rates of attrition observed in the Western 
Cape may overstate the true rates of attrition, since almost half of all Western Cape patients 
not retained in care by 12 months are considered „lost to follow-up‟, and may therefore still 
be receiving ART elsewhere. Setting the standard deviation for the gamma prior on R to 0.4 
yields 2.5 and 97.5 percentiles of 0.38 to 1.92 respectively, which adequately reflects the 
extent of uncertainty around the ratio of the true attrition rate to that recorded in the Western 
Cape province. 
 
Table 3: Cumulative attrition by 12 months after starting ART in South African patients  
Study Location n Attrition 
Boulle et al 
23
 Whole of Western Cape 12587 14.7% 
Bekker et al 
25
 Gugulethu, Western Cape 1139 9% 
Coetzee et al 
26
 Khayelitsha, Western Cape 287 13.7% 
Fatti et al 
27
 Sites in KwaZulu-Natal, Eastern Cape,  
   Western Cape, Mpumalanga 
29203 17.9% 
Ford et al 
28
 Lusikisiki, Eastern Cape 1025 24.9% 
Mutevedzi et al 
29
 Umkhanyakude, KwaZulu-Natal 5719 16.0% 
Rosen et al 
30
 Sites in Gauteng, Eastern Cape, Mpumalanga 400 28.0% 
Vella et al 
31
 Sites in KwaZulu-Natal 2835 19% 
 
It is important to note that in our model, the attrition rates 0  and 1  are defined as the rates 
at which patients permanently stop ART, either due to death or due to the patient not 
collecting their medication. Our model does not allow for increases in rates of attrition over 
time, although various South African studies have noted marked trends towards greater loss 
to follow-up over time.
27, 32, 33
 The reasons for not allowing for a trend towards increased 
attrition over time are: 
 It has been acknowledged that some of the apparent increase in loss to follow-up may 
be due to increases in administrative error,
32
 i.e. because of the increasingly large 
volumes of patients, it is difficult to keep accurate records of when patients visit the 
clinics. 
 Some of the apparent increase in loss to follow-up is also due to increasing levels of 
decentralization in the provision of ART, with patients not informing the clinic at 
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which they started ART of their move to a nearer clinic. These patients who remain 
on ART despite being lost to follow-up are not included in our definition of attrition. 
 Some of the apparent increase in loss to follow-up is also due to patients temporarily 
stopping ART; patients who started ART in the early years of the ART programme 
and resumed ART after interrupting therapy would not be considered lost to follow-up 
now, but patients who recently interrupted ART and have not yet resumed ART 
would be considered lost to follow-up in ART programme reporting. These patients 
who temporarily interrupt ART are not included in our definition of attrition. 
 To the extent that there is a real increase in the rate at which patients stop taking their 
medication, it is likely to be partially offset by reductions in mortality rates. These 
reductions in mortality rates are likely to be the result of trends towards increasing 
baseline CD4 counts in patients starting ART over time.
34
 The net effect of rising 
treatment discontinuation and declining mortality may be relatively little change in 
overall rates of attrition over time. 
 
(d) Proportion of ART attrition that is attributable to death 
 
Although rates of loss to follow-up are often reported to be higher than rates of mortality in 
patients receiving ART, a recent review has shown that a substantial proportion of patients 
„lost to follow-up‟ are actually dead, and many are in fact still receiving ART in other 
treatment centres
35
 (the latter are not included in our definition of „attrition‟). In this review, 
the average proportion of patients lost to follow-up after ART initiation who were found to 
have died when subsequently traced was 46% in African studies (range 27-87%). 
Unpublished data from the IeDEA Southern Africa Collaboration suggest that after correcting 
for under-reporting of deaths, mortality rates after ART initiation are approximately 75% of 
the average ART attrition rates assumed in section (c). The 75% proportion may be an under-
estimate of the true mortality fraction, since the IeDEA Collaboration consists mostly of 
relatively well-resourced ART programmes from urban areas, which are not likely to be 
representative of the ART programme at a national level, and which may therefore have 
relatively low mortality. However, 75% could also be an over-estimate of the true mortality 
fraction, since the model parameter ν is defined to exclude individuals who died after they 
stopped taking ART, and the mortality rate estimated from the IeDEA data does not separate 
out „deaths on ART‟ from „deaths off ART‟. The prior distribution assigned to the ν 
parameter is therefore a beta distribution with a mean of 0.75 and standard deviation of 0.10 
(the 2.5 and 97.5 percentiles of this distribution are 0.53 and 0.92 respectively). 
 
(e) Bias in reported ART programme statistics 
 
It is quite likely that there is some degree of bias in reported ART programme statistics, 
though it is not immediately obvious whether the bias would be towards overstatement or 
understatement of patient totals. This section discusses the types of reporting error that are 
likely to emerge and the extent to which they may bias the reported patient totals. We 
consider separately two types of reported ART programme statistics: reported numbers of 
patients cumulatively enrolled and reported numbers of patients currently receiving ART. 
 
Reported numbers of patients cumulatively enrolled 
 
From the cumulative patient totals, it is possible to calculate )(tS , the reported number of 
patients starting ART in year t, by subtracting the cumulative total at time t from the 
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cumulative total at time t + 1. The true number of patients starting ART between time t and 
time t + 1, S(t), is assumed to be some multiple of the reported number. Mathematically, 
 )(1)()( 0 tZbtStS  , where b0Z(t) is an adjustment factor to allow for bias in the reported 
data. The b0Z(t) parameters are unknown, and are therefore included in the Bayesian analysis. 
Prior distributions are specified for the b0Z(t) factor in each year, and each prior is assumed to 
be a normal distribution with a mean of 0 (i.e. assuming that on average the reported totals 
are correct) and standard deviation of b0, so that Z(t) is a standard normal variate. The 
standard deviation, b0, is set by noting that there are two potential sources of bias in reporting 
cumulative numbers of patients enrolled on ART. 
 
The first source of bias is double-counting. This may occur because patients who move from 
one clinic to another get counted as having started ART twice (once at the first clinic and 
once at the second clinic). In a worst-case scenario, if all patients moving between clinics are 
double-counted, the ratio of the number of patients incorrectly counted as starting ART in 










where N(t) is the total number of patients on ART at time t, α is the annual rate at which 
patients are lost to follow-up and χ is the proportion of patients lost to follow-up who move to 
a different clinic. (Note that   does not include the patients who are known to transfer out, 
as these patients would typically receive a referral letter informing their new treatment 
provider of their previous receipt of ART, so that they would not be double-counted.)   
 
Estimates from previous analyses
24
 suggest that the ratio   )()1()(5.0 tStNtN   is 
typically between 1 and 2. Annual rates of loss to follow-up in South African ART 
programmes are typically between 5% and 15%, though varying according to the maturity of 
the programme.
32
 Two separate studies in Johannesburg have found  the proportion of 
patients lost to follow-up who initiate ART elsewhere to be 11.4% and 25.4%.
36, 37
 If it is 
assumed that χ is unlikely to exceed 0.3, then the ratio of the over-count to the true number of 
patients starting ART is unlikely to exceed 2 × 0.15 × 0.3 = 0.075. 
 
The second potential source of bias is late reporting of patients who have started ART. If the 
number of patients cumulatively enrolled on ART is correctly reported at the start of the year, 
but there is an average delay of one month in the reporting of new patients, by the end of the 
year, one might expect that the estimated number of new patients )(tS  to under-state the true 
number by one twelfth (0.083), if it is assumed that patients were enrolled uniformly over the 
course of the year. Conversely, if the cumulative number on ART at the end of the year is 
correctly reported, but the number at the start of the year is subject to late reporting, the 
estimated number of new patients )(tS  will over-state the true number. However, because 
numbers of patients enrolled are generally increasing over time, one would generally expect 
the bias due to late reporting to be a downward bias rather than an upward bias. 
 
The net effect of any over-statement due to double-counting and any under-statement due to 
late reporting is likely to be relatively small, and we consider it unlikely that the factor b0Z(t) 
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would be either less than -0.12 or more than 0.12. The standard deviation b0 parameter is 
therefore set to 0.06, so that the prior 95% confidence interval on b0Z(t) is from -0.12 to 0.12. 
 
Reported numbers of patients currently receiving ART 
 
Some provinces have recently switched to reporting the numbers of patients currently on 
ART rather than the numbers of patients cumulatively enrolled on ART – this has also been 
the standard reporting practice in the private and NGO sectors for several years. In this 
situation, the true number of patients currently on ART (or temporarily interrupted) is 
assumed to be some multiple of the reported number of patients on ART at time t, )(tN . 
Mathematically,  )(1)()( 1 tZbtNtN  , where )(1 tZb  is an adjustment factor to allow for 
bias in the reported data. As before, prior distributions are specified for the )(1 tZb  factor in 
each year, and each prior is assumed to be a normal distribution with a mean of 0 and 
standard deviation b1.  
 
As in the estimation of S(t), late reporting could lead to under-estimation of N(t). If there is an 
average delay of 1 month in the reporting of patients who have started ART, then the extent 
of the under-estimation would be roughly   )())()1((5.0121 tNtStS   at time t. 
Estimates from previous analyses
24
 suggest that the ratio )())()1((5.0 tNtStS   is typically 
around 0.8, so that a 1-month reporting delay would correspond to a bias of roughly 0.8/12 = 
6.7%.  
 
An important source of bias in the context of cross-sectional data relates to the inclusion and 
exclusion of individuals who have stopped ART. Patients who have temporarily interrupted 
ART are included in our modelled number of patients on ART, N(t), but might not be 
included in the reported number of patients on ART, )(tN . However, patients who have 
permanently discontinued ART are excluded from N(t) but might be included in )(tN . In 
order to determine the net extent of the bias due to the inclusion/exclusion of treatment 
interrupters, it is necessary to make the following assumptions: 
 Firstly, it is assumed that patients temporarily interrupt ART at a monthly rate of β. 
This is distinct from permanent ART interruption. Kranzer et al
38
 found that in 
Masiphumelele, the annual rate at which patients discontinue ART is 12.8 per 100 
person years, and that 33% of these individuals ultimately resume ART. This suggests 
a value for β of 0.128 × 0.33 / 12 = 0.0035. 
 Secondly, it is assumed that patients permanently discontinue ART, or transfer to 
ART at another centre without informing their original treatment centre (so-called 
„silent transfer‟), at a monthly rate of γ. Based on the same data summarized in the 
previous point, this parameter might be estimated as 0.128 × (1 – 0.33) / 12 = 0.0071.  
 Thirdly, it is assumed that when reporting numbers of patients currently on ART, 
programmes count patients as being on ART if they are not more than w months late 
for a scheduled visit. In the Western Cape, patients are included in the total number of 
patients on ART if they are not more than 3 months late for their most recent 
scheduled visit, i.e. w = 3.
39
 Other provinces have been instructed to use the same 
definition in reporting numbers of patients currently on ART, but it is not clear to 
what extent this recommendation is being followed (Meg Osler, personal 
communication). In other ART programmes in developing countries, definitions have 





 Fourthly, it is assumed that patients who resume ART after interrupting therapy do so 
after an average of 7 months, based on the median time to ART resumption observed 
in the community of Masiphumelele.
38
 In a review of other studies that have estimated 




Based on these assumptions, patients who permanently discontinue ART are included in 
)(tN  but excluded from N(t) for an average of w months, and patients who temporarily 
discontinue ART are included in N(t) but excluded from )(tN  for an average of (7 – w) 
months. (By including in the definition of γ those individuals who have silently transferred, 
we are also assuming that individuals who silently transfer are double-counted in )(tN  for an 
average of w months.) The percentage by which )(tN  exceeds N(t) is approximately  
 
  ww  7 , 
 
which is 0.7% when w = 3 months. For values of w between 0 and 6 months, the percentage 
would be between -2.5% and 3.9%. 
 
A third potential source of bias is replacement of current totals with cumulative totals in sites 
that lack the capacity to update their records of numbers of patients currently on ART. This 
may occur even when the overall policy in the province is to report numbers currently on 
ART. There is anecdotal evidence of this occurring in the Western Cape, where the overall 
policy has always been to report numbers of patients currently on ART, but since 2007 lack 
of technical support has led to certain clinics calculating the numbers of patients „currently‟ 
on ART by simply adding the number of patients starting ART in the current period to the 
number reported as having been on ART in the previous period, without making any 
allowance for patients who have stopped ART (Meg Osler, personal communication). This 
would lead to some over-estimation of the numbers of patients currently on ART, but it is 
difficult to quantify the likely extent of this over-estimation. 
 
In summary, there are three sources of bias to be considered when estimating N(t) from )(tN : 
bias due to late reporting (bias as low as -6.7% if there is a one-month average delay), bias 
due to inclusion/exclusion of ART interrupters and double counting of transfers (bias 
between -2.5% and 4%) and bias due to reporting of cumulative totals in some clinics (bias 
>0). We assume that the net bias, adding all three sources of error together, would be unlikely 
to be more than 8% (absolute) of the true total, and have therefore set the standard deviation 




It is important to note that the Z(t) factor is applied to all data sources in year t, both numbers 
newly enrolled and current totals (although with different standard deviations). It could be 
argued that it would be more realistic to allow different values of Z(t) for different data 
sources reported in the same year, since different provinces and different providers are likely 
to have different reporting systems. By using the same value of Z(t) for all data sources in 
year t, we are being deliberately conservative, allowing for more uncertainty in the accuracy 
of the reported ART statistics than would actually exist if the biases in the totals reported by 
different provinces/providers were independent of one another. However, it is debatable 
10 
 
whether biases are truly independent, and assuming independence could lead to some under-
estimation of the extent of the uncertainty in the ART programme statistics. 
 
It is also important to note that this approach does not make assumptions about correlation 
between Z(t) and Z(t+1). Positive correlation might be expected when dealing with reported 
numbers of patients currently on ART, since the same sources of bias are likely to persist 
from one year to the next. However, negative correlation might be expected when dealing 
with reported numbers of patients cumulatively enrolled. For example, if the cumulative 
patient total is exaggerated at the start of year t, but the cumulative totals reported at the start 
of years t – 1 and t + 1 are correct, then the number of patients starting ART in year t – 1 will 
be overstated, but the number of patients starting ART in year t will be understated. Because 
of the uncertainty about whether correlation is positive or negative, zero correlation has been 
assumed.  
 
(f) Priors on model outputs 
 
Although there is considerable uncertainty regarding the HIV parameters referred to in the 
previous sections, it is clear that any combination of model parameters that leads to an 
estimate of ART need smaller than the estimated number of patients starting ART in South 
Africa cannot be plausible. We therefore specify priors on the model outputs to prevent these 
implausible parameter combinations from being included in the posterior sample. The model 
output of interest is rg(t), the annual rate at which ART is initiated in year t, in ART-eligible 
individuals of sex g. The inverse of this rate is the average time from becoming eligible for 
ART to starting ART (in years). Individuals receiving pre-ART care should receive CD4 
testing every 6 months, so that individuals in pre-ART care would be determined to be ART-
eligible on average 3 months after their CD4 count drops below the ART-eligible threshold. 
If individuals are newly-diagnosed and determined to be ART-eligible, there is also likely to 
be a delay before they start ART. Ingle et al
42
 found that in the Free State ART programme, 
the median time from enrolment into the ART programme to starting ART was 95 days, 
though this median dropped from 122 days in 2004 to 78 days in 2007. Some of this delay 
was due to a 3-week drug readiness training programme that all patients had to complete, and 
some of the delay was due to patients being referred to clinics where they could start ART. In 
a Cape Town study,
43
 the median time between enrolment into the ART programme and ART 
initiation was 34 days, although this did not include the time taken to assess ART eligibility. 
In a Durban study,
44
 the average time from when the CD4 test was performed (to assess 
eligibility) to when ART training began was 3.6 months. In another Cape Town study,
45
 
69.2% of patients who were diagnosed HIV-positive and had CD4 counts <200/μl started 
ART within 2 months of HIV diagnosis. Using point-of-care CD4 testing, Faal et al
46
 found 
that 65% of patients in Johannesburg who were newly diagnosed and ART-eligible started 
ART within 3 months. However, because point-of-care CD4 testing is not generally used in 
South Africa, and delays in the collection of CD4 testing are usually significant, this is 
probably an over-estimate of the proportion of patients who would normally start ART within 
3 months of diagnosis. Based on the reviewed evidence, it is considered unlikely that the 
average time from when individuals become ART-eligible to when they start ART would be 
less than 2 months (corresponding to rg(t) = 6). The prior distribution for rg(t) is therefore set 
to be uniform on the interval [0, 6], for all values of t and g. This means that any parameter 
combination that leads to a modelled rate of ART initiation > 6 per annum (for males or 




3. Likelihood function 
 
The likelihood function measures how well the model fits the data, for a given set of model 
input parameters. In this analysis, two sources of data are included in the definition of the 
likelihood: CD4 data from surveys of HIV-positive adults, and age-specific HIV prevalence 
data from household surveys. A likelihood function is defined separately for each data 
source, and the total likelihood is the product of likelihood functions calculated for each data 
source. 
 
(a) Likelihood function for CD4 data 
 
Three different South African studies have measured the proportions of HIV-infected adults 
in different CD4 categories. The results of these three studies are summarized in Table 4. All 
three studies were conducted when access to antiretroviral treatment in South Africa was 
fairly limited, and the proportions can therefore be assumed to be representative of untreated 
individuals. 
 
















Auvert et al 
9
 2002 Households in  
   Orange Farm 
196 46.0 25.6 18.9 9.5 
Rehle and Shisana
47
 2004 Teachers 444 27.9 19.8 30.0 22.3 
Connelly et al
48
 2005 Health workers 74 35.1 17.6 28.4 18.9 
 
Suppose that if a set of parameters, represented by vector ψ , is entered into the model, the 
model estimates that the proportions of ART-naïve individuals in stage i of HIV infection, in 
year tj, is ),( ψji t  (there are four possible stages of infection corresponding to the four 
untreated CD4 stages in Figure 1). Further suppose that the observed numbers of infected 
individuals in the j
th
 study, conducted in year tj, who are in stage i is nij. It can then be 
assumed that the nij terms are multinomially distributed, so that the likelihood function in 
respect of the j
th
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where nj is the total number of HIV-positive adults in the  j
th
 study. This is a fixed effects 
model, i.e. it is assumed that the CD4 distribution is the same for all South African 
populations that we might choose to sample. The assumption of a fixed effects framework is 
probably unrealistic, since some populations may be genetically different from others, some 
populations may be experiencing more advanced epidemics than others, etc. To account for 
variation in proportions between sub-populations, we define ij as the true proportion of 
infected individuals in stage i, in the j
th
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where jρ  and ),( ψπ jt  represent the vectors of ij and ),( ψji t  values respectively. Note 
that from the properties of the Dirichlet distribution, 
 

















so that the   variable controls the variance of the random effects, and hence the variability in 
CD4 proportions across studies. For the purpose of this analysis, the   parameter is fixed at 
188.5, the maximum likelihood estimate obtained in a previous analysis of the same CD4 
data.
49
 The likelihood function in respect of study j is then 
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where jn  represents the vector of nij values. This likelihood can be more fully expressed as 
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Note that after factoring out the terms that are independent of ij in the above equation, the 
integral is itself of a Dirichlet form, and therefore integrates to 1 with the multiplication of an 










































 .   
 
For the purpose of simulating the posterior distribution, it is sufficient to calculate the log of 
the likelihood function and to exclude those terms that are independent of the parameters that 
we are trying to estimate (i.e. terms independent of ψ ). The total log likelihood is obtained 
by summing the values of the log likelihood for each individual study: 
 









jijiijC ttnl ψψψn  , 
 
where n is the matrix of nij values. 
 
(b) Likelihood function for HIV prevalence data 
 
This component of the likelihood function is defined with reference to the HIV prevalence 
levels measured, by age and sex, in the national household surveys conducted by the Human 
13 
 




 Suppose that  ψtxgH ,,  is the 
model estimate of HIV prevalence in individuals of sex g, aged x to x + 4 in year t, where the 
vector ψ  represents the values of the model input parameters. The corresponding prevalence 
of HIV actually measured in the HSRC survey is represented by txgy ,, . It is assumed that if 
ψ  is the true set of parameter values, then the difference between the logit-transformed 
model estimate and the logit-transformed observed prevalence is normally distributed with 











































where  2 ,,,, ,0~ txgtxg N  , representing the random sampling error in the survey. The logit 
transformations ensure that the error terms are closer to normality and that the model error 
terms are roughly independent of the level of HIV prevalence. The 
2
,, txg  values are estimated 
from the 95% confidence intervals that have been published for the various survey estimates. 
The likelihood in respect of a single measurement is then calculated as 
 
   





























As before, it is sufficient to calculate the log of the likelihood and to exclude those terms that 
are independent of ψ . The total log likelihood is obtained by summing the values of the log 
likelihood for each prevalence measurement: 
 
 




















where y represents the matrix of txgy ,,  values. In this analysis, only HIV prevalence 
measurements in the 15-49 age range are used in calculating the likelihood, so that the 
summation in relation to x is for age groups 15-19, 20-24, …, 45-49.  
 
Finally, the log likelihood in respect of the CD4 data,  ψn |Cl , is added to the log likelihood 
in respect of the HIV prevalence data,  ψy |Hl , to obtain the log of the total likelihood. 
 
4. Posterior simulation 
 
The posterior distribution represents the synthesis of the prior distributions assigned to the 
different parameters and the likelihood values calculated for each parameter combination. 
The likelihood function is simulated numerically, using Sampling Importance Resampling 
(SIR).
52, 53
 This is a three-step procedure. In the first step of the algorithm, 10 000 parameter 
combinations are randomly sampled from the prior distributions described in sections 2(a)-(e) 
(suppose that iψ  represents the i
th
 parameter combination that is sampled). In the second step 
of the algorithm, the log likelihood is calculated for each parameter combination (  iCl ψn |  + 
14 
 
 iHl ψy | ), and an importance weight is assigned to each parameter combination based on 
this log likelihood. For the i
th
 parameter combination, this weight is calculated as 
 
 




























where A is the set of model parameter combinations that yield estimates of rg(t) < 6 for all g 
and t. Setting Wi = 0 if Ai  means applying the prior distribution described in section 2(f) to 
the model outputs. In this respect our approach differs from the standard Bayesian approach. 
Bayesian melding generalizes the standard Bayesian approach by allowing for prior 




In the final step of the SIR algorithm, a „resample‟ of 1 000 parameter combinations is drawn 
from the original sample, using the {Wi} values as sample weights (sampling is with 
replacement). This sample constitutes a random sample from the posterior distribution. The 
model is then run for each parameter combination in this posterior sample in order to obtain 
an approximation to the distribution of model outputs (this distribution is summarized in 
terms of its mean and 95% confidence interval, for each model output). 
 
In this analysis, the posterior sample of 1 000 parameter combinations included 410 unique 
parameter combinations, and the most frequently sampled parameter combination accounted 
for only 13 parameter combinations (1.3% of the total). This indicates that the posterior 
sample is not unduly influenced by single parameter combinations that have unusually high 
likelihood values. 
 
Table 5 compares the prior and posterior distributions for each of the model parameters. 
Posterior estimates suggest a more rapid rate of progression to CD4 <350/μl than assumed a 
priori, based on rates of CD4 decline in developed countries. However, rates of mortality 
after CD4 drops below 350/μl are marginally lower than those that have been assumed a 
priori, based on data in other African countries. The posterior mean for the R parameter is 
substantially lower than the prior mean (0.74 compared to 1.00), which suggests that the true 
rate of attrition in South Africa is lower than has been observed in the Western Cape. This is 
probably because our definition of attrition excludes individuals who temporarily interrupt 
ART or transfer between ART services without informing the clinic at which they originally 
received ART (both groups are likely to comprise a substantial proportion of patients 
considered „lost to follow-up‟ in the Western Cape ART programme). The relatively low rate 
of attrition estimated in this analysis explains why the estimates of total patient numbers 






Table 5: Comparison of prior and posterior distributions 
Parameter (symbol)  
Prior distribution 
(mean, 95% CI) 
Posterior distribution 
(mean, 95% CI) 
Parameters for untreated adults    
   Annual rate of progression from CD4 >500 to 350-500 λ1 0.30 (0.19-0.43) 0.34 (0.28-0.39) 
   Annual rate of progression from CD4 350-500 to 200-349 λ2 0.40 (0.26-0.58) 0.48 (0.40-0.58) 
   Annual rate of progression from CD4 200-349 to <200 λ3 0.35 (0.23-0.50) 0.32 (0.25-0.39) 
   Annual rate of HIV mortality if CD4 <200 λ4 0.25 (0.13-0.40) 0.21 (0.16-0.27) 
   Ratio of HIV mortality at CD4 200-349 to HIV mortality  
      at CD4 <200 
θ 0.15 (0.07-0.26) 0.13 (0.05-0.24) 
Parameters for treated adults    
   Relative rate of attrition (as multiple of WC estimate) R 1.00 (0.38-1.92) 0.74 (0.27-1.34) 
   Proportion of permanent loss to care that is due to death ν 0.75 (0.53-0.92) 0.74 (0.53-0.92) 
Bias factors Z(t)   
   Year 2001  0 (-1.96 to 1.96) 0.02 (-2.04 to 1.79) 
   Year 2002  0 (-1.96 to 1.96) 0.09 (-1.81 to 2.16) 
   Year 2003  0 (-1.96 to 1.96) 0.00 (-1.90 to 1.94) 
   Year 2004  0 (-1.96 to 1.96) -0.07 (-2.32 to 1.99) 
   Year 2005  0 (-1.96 to 1.96) 0.06 (-2.08 to 1.99) 
   Year 2006  0 (-1.96 to 1.96) 0.11 (-1.90 to 2.11) 
   Year 2007  0 (-1.96 to 1.96) 0.05 (-2.03 to 2.22) 
   Year 2008  0 (-1.96 to 1.96) 0.07 (-2.15 to 1.97) 
   Year 2009  0 (-1.96 to 1.96) -0.01 (-1.85 to 2.11) 
   Year 2010  0 (-1.96 to 1.96) -0.12 (-1.96 to 1.76) 
   Year 2011  0 (-1.96 to 1.96) -0.39 (-2.41 to 1.44) 
WC = Western Cape 
 
In general, average posterior estimates of bias in reported ART statistics are not substantially 
different from zero. However, in 2011 there appears to be a more substantial upward bias in 
the reported ART programme statistics (the average values of )2011(0Zb  and )2011(1Zb  are 
-0.023 and -0.016 respectively, suggesting true patient numbers are roughly 2% lower than 
those reported, on average). This may be because high values of Z(2011) are likely to lead to 
implausibly high rates of ART initiation in the most recent year (rg(t) > 6), and such 
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